CDKN2A and melanoma: Since the CDKN2A–CDK4/CDK6–cyclin D axis is often disrupted in melanoma CDK4/CDK6 inhibitors (e.g., abemaciclib and palbociclib) are predicted to be effective in the treatment of melanoma (99, 100).